Literature DB >> 6259406

Captopril in various forms of severe therapy-resistant hypertension.

A Studer, T Lüscher, W Siegenthaler, W Vetter.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1981        PMID： 6259406     DOI： 10.1007/bf01477284

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN： 0023-2173


× No keyword cloud information.
  23 in total

1.  Reversible renal failure during treatment with captopril.

Authors:  P R Farrow; R Wilkinson
Journal:  Br Med J       Date:  1979-06-23

2.  Problems connected with plasma renin activity measurements by angiotensin I radioimmunoassay.

Authors:  R Beckerhoff; J Nussberger; W Vetter; W Siegenthaler
Journal:  Horm Metab Res       Date:  1975-07       Impact factor: 2.936

3.  Interruption of the renin-angiotensin system in hypertensive patients by captopril induces sustained reduction in aldosterone secretion, potassium retention and natruiresis.

Authors:  S A Atlas; D B Case; J E Sealey; J H Laragh; D N McKinstry
Journal:  Hypertension       Date:  1979 May-Jun       Impact factor: 10.190

4.  Captopril: reversible renal failure with severe hyperkalaemia.

Authors:  A Grossman; D Eckland; P Price; C R Edwards
Journal:  Lancet       Date:  1980-03-29       Impact factor: 79.321

5.  Immune-complex glomerulopathy in patients treated with captopril.

Authors:  S J Hoorntje; C G Kallenberg; J J Weening; A J Donker; T H The; P J Hoedemaeker
Journal:  Lancet       Date:  1980-06-07       Impact factor: 79.321

6.  Nephrotic syndrome in patient on captopril.

Authors:  E J Prins; S J Hoorntje; J J Weening; A J Donker
Journal:  Lancet       Date:  1979-08-11       Impact factor: 79.321

7.  Long-term effects of captopril (SQ14 225) on blood-pressure and hormone levels in essential hypertension.

Authors:  C I Johnston; J A Millar; B P McGrath; P G Matthews
Journal:  Lancet       Date:  1979-09-08       Impact factor: 79.321

8.  Discrepancy between antihypertensive effect and angiotensin converting enzyme inhibition by captopril.

Authors:  B Waeber; H R Brunner; D B Brunner; A L Curtet; G A Turini; H Gavras
Journal:  Hypertension       Date:  1980 Mar-Apr       Impact factor: 10.190

9.  A specific orally active inhibitor of angiotensin-converting enzyme in man.

Authors:  R K Ferguson; G A Turini; H R Brunner; H Gavras; D N McKinstry
Journal:  Lancet       Date:  1977-04-09       Impact factor: 79.321

10.  Proteinuria during long-term captopril therapy.

Authors:  D B Case; S A Atlas; J A Mouradian; R A Fishman; R L Sherman; J H Laragh
Journal:  JAMA       Date:  1980-07-25       Impact factor: 56.272
View more
  6 in total

1.  Long-term experience with captopril in severe hypertension.

Authors:  J Havelka; H J Boerlin; A Studer; P Greminger; W Tenschert; T Luescher; W Siegenthaler; W Vetter; P Walger; H Vetter
Journal:  Br J Clin Pharmacol       Date:  1982       Impact factor: 4.335

2.  Subjective and objective assessment of enalapril in primary Raynaud's phenomenon.

Authors:  V F Challenor; D G Waller; R A Hayward; M J Griffin; O S Roath
Journal:  Br J Clin Pharmacol       Date:  1991-04       Impact factor: 4.335

3.  Elevated angiotensin-I-converting enzyme (ACE) in patients with essential hypertension.

Authors:  H Schweisfurth; A Kment; H Dahlheim; B E Strauer
Journal:  Klin Wochenschr       Date:  1982-01-04

Review 4.  Angiotensin converting enzyme inhibitors in Raynaud's phenomenon.

Authors:  V F Challenor
Journal:  Drugs       Date:  1994-12       Impact factor: 9.546

5.  Aldosterone and prolactin responsiveness after prolonged treatment of congestive heart failure with captopril.

Authors:  E Jungmann; H Störger; P H Althoff; D Hadler; W Fassbinder; W D Bussmann; M Kaltenbach; K Schöffling
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

6.  The antihypertensive effect of captopril in severe essential, renovascular, renal and transplant renovascular hypertension.

Authors:  G Schwietzer; W Oelkers
Journal:  Klin Wochenschr       Date:  1982-08-16
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.